¡Ya estamos en ! Descubre más

RayzeBio, Inc. Common Stock

RYZB

Capitalización de mercado USD 3750 M

Excluida de cotización

RYZB dejó de cotizar en bolsa el 23 de febrero de 2024.

Volver al ranking

Acerca de: RayzeBio inc is a company operating as vertically integrated radiopharmaceutical therapeutics company. The main objective of the company is defeating cancer with radiopharmaceutical medicines. It has a created a pipeline of multiple drug candidates, in therapeutic areas with significant market opportunities. They have a portfolio of potential RPT drug and development candidates that includes late-stage clinical programs, development programs and discovery programs.

Empleados: 88

Atención médica Fabricantes de medicamentos - General

Noticias

Positivo

Neutral

Negativo

Sentimiento 3 meses

Positivo 0%

Neutral 0%

Negativo 0%

Bristol Myers Squibb Announces Expiration of RayzeBio Tender Offer

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that its previously announced tender offer (the “Offer”) to acquire all of the outstanding shares of RayzeBio, Inc. (Nasdaq: RYZB) common stock for a purchase price of $62.50 per share in cash, or approximately $4.1 billion, expired at one minute after 11:59 p.m., Eastern Time, on February 22, 2024 (the “Expiration Time”). Equiniti Trust Company, the depositary for the Offer, has advised that, as of the Expiratio.

Bristol Myers Squibb Announces Expiration of RayzeBio Tender Offer

Bristol Myers Squibb and RayzeBio Announce Expiration of HSR Act Waiting Period

PRINCETON, N.J. & SAN DIEGO--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) and RayzeBio, Inc. (Nasdaq: RYZB) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, or HSR Act, in connection with Bristol Myers Squibb's previously announced tender offer to acquire all of the outstanding shares of RayzeBio common stock for a purchase price of $62.50 per share in cash, or approximately $4.1 billion. The expiration of the waiting peri.

Bristol Myers Squibb and RayzeBio Announce Expiration of HSR Act Waiting Period

IPO watch 2024: Which new stocks will hit the market?

Among 2023 IPOs, one of the top performers was RayzeBio Inc. NASDAQ: RYZB, a biotech that's out of play now because it's being acquired by Bristol Myers Squibb Co. NYSE: BMY.

Cramer names biopharma companies to watch as industry mergers start to pile up

CNBC's Jim Cramer pointed out the numerous mergers and acquisitions across the biopharma industry.

RAYZEBIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RayzeBio, Inc. - RYZB

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of RayzeBio, Inc. (NasdaqGM: RYZB) to Bristol-Myers Squibb Company (NYSE: BMY). Under the terms of the proposed transaction, shareholders of RayzeBio will receive $62.50 in cash for each share of RayzeBio that they own. KSF is seeking to determine whether this consideration and the process that led to it are adeq.

RAYZEBIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RayzeBio, Inc. - RYZB

Fusion Pharma climbs as analyst flags radiopharmaceutical company as potential merger target

Fusion Pharmaceuticals Inc.'s stock FUSN, +16.69% was up by 5.3% in premarket trading on Wednesday, as analysts at Oppenheimer highlighted the company as a potential merger target. Fusion Pharmaceuticals “is potentially the sole remaining clinical-stage, targeted radiopharm player with a robust supply chain,” analysts said in a research note on Wednesday.

Bloomberg Markets and Finance

Bristol to Buy Drug Developer RayzeBio for $4.1 Billion

Bristol Myers Squibb Co. agreed to buy radiological drug developer RayzeBio Inc. for about $4.1 billion, the latest deal in a buying spree to bolster its pipeline. Bloomberg's Madison Mueller reports.

CNBC Television

The state of pharmaceuticals: Bristol-Myers Squibb's plan to buy RayzeBio

Jared Hopkins, Wall Street Journal, joins 'The Exchange' to discuss Bristol-Myers Squibb's plan to buy RayzeBio.

Bristol Myers Squibb Buys RayzeBio, Its Second Multibillion-Dollar Deal in Days

RayzeBio Inc. (RYZB) shares skyrocketed Tuesday after Bristol Myers Squibb Co. (BMY) said it was buying the radiopharmaceutical therapy company for $4.1 billion to expand its cancer treatment options. It was the second multibillion-dollar acquisition for Bristol Myers Squibb in less than a week.

Midday Movers: Intel's Israel Deal, Bristol-Myers Squibb Buys RayzeBio

Christmas may be over, but the so-called “Santa Claus rally” continued for U.S. equities at midday in the shortened final trading week of 2023. The Dow, S&P 500, and Nasdaq were all in positive territory.

Ver rankings de noticias

Gráficos de precios implementados con Lightweight Charts™